Erica M Fallon1, Hau D Le, Mark Puder. 1. Department of Surgery and Vascular Biology Program, Children's Hospital Boston, Boston, Massachusetts 02115, USA.
Abstract
PURPOSE OF REVIEW: Parenteral nutrition-associated liver disease (PNALD) is the most severe complication of long-term parenteral nutrition. Its cause remains unclear, although recent studies suggest that the omega-6 polyunsaturated fatty acids in plant oil-based lipid emulsions and the associated phytosterols contribute to the development of hepatotoxicity. In contrast, fish oil-based lipid emulsions are composed mainly of omega-3 polyunsaturated fatty acids and are hypothesized to be hepatoprotective. This review will discuss fish oil-based lipid emulsions in the prevention of PNALD. RECENT FINDINGS: In several animal models of PNALD, the use of an intravenous fish oil-based lipid emulsion improved parenteral nutrition-associated cholestasis without resultant essential fatty acid deficiency or growth impairment. Following these results and preliminary human data, an open trial for compassionate use was initiated, followed by a randomized controlled trial to evaluate the current management of pediatric PNALD. To date, at the author's institution, more than 130 children with PNALD have been treated with Omegaven, a fish oil-based emulsion, with improved liver function among most patients. SUMMARY: PNALD remains the most severe complication of long-term parenteral nutrition with an unclear pathophysiology. However, the use of a fish oil-based emulsion appears efficacious and hepatoprotective.
PURPOSE OF REVIEW: Parenteral nutrition-associated liver disease (PNALD) is the most severe complication of long-term parenteral nutrition. Its cause remains unclear, although recent studies suggest that the omega-6 polyunsaturated fatty acids in plant oil-based lipid emulsions and the associated phytosterols contribute to the development of hepatotoxicity. In contrast, fish oil-based lipid emulsions are composed mainly of omega-3 polyunsaturated fatty acids and are hypothesized to be hepatoprotective. This review will discuss fish oil-based lipid emulsions in the prevention of PNALD. RECENT FINDINGS: In several animal models of PNALD, the use of an intravenous fish oil-based lipid emulsion improved parenteral nutrition-associated cholestasis without resultant essential fatty acid deficiency or growth impairment. Following these results and preliminary human data, an open trial for compassionate use was initiated, followed by a randomized controlled trial to evaluate the current management of pediatric PNALD. To date, at the author's institution, more than 130 children with PNALD have been treated with Omegaven, a fish oil-based emulsion, with improved liver function among most patients. SUMMARY: PNALD remains the most severe complication of long-term parenteral nutrition with an unclear pathophysiology. However, the use of a fish oil-based emulsion appears efficacious and hepatoprotective.
Authors: Ana M G A Sant'Anna; Eyad Altamimi; Rose-Frances Clause; Joanne Saab; Heather Mileski; Brian Cameron; Peter Fitzgerald; Guilherme M Sant'Anna Journal: Can J Gastroenterol Date: 2012-05 Impact factor: 3.522
Authors: Camilia R Martin; Deborah A Dasilva; Joanne E Cluette-Brown; Clementina Dimonda; Ashley Hamill; Abdul Q Bhutta; Emmanuel Coronel; Michael Wilschanski; Alisa J Stephens; David F Driscoll; Bruce R Bistrian; James H Ware; Munir M Zaman; Steven D Freedman Journal: J Pediatr Date: 2011-06-12 Impact factor: 4.406
Authors: Karim C El Kasmi; Aimee L Anderson; Michael W Devereaux; Padade M Vue; Wujuan Zhang; Kenneth D R Setchell; Saul J Karpen; Ronald J Sokol Journal: Sci Transl Med Date: 2013-10-09 Impact factor: 17.956
Authors: Hubertine M E Willems; Jeremy S Stultz; Molly E Coltrane; Jabez P Fortwendel; Brian M Peters Journal: Antimicrob Agents Chemother Date: 2019-10-22 Impact factor: 5.191